Company: XAIR
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021561
Chunk: 34

Company: Beyond Air, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
30, 2024 were immaterial.

    21

BEYOND
AIR, INC. AND SUBSIDIARIES

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE
11 SEGMENTS

During
the three months ended September 30, 2025, NeuroNos issued and sold 166,667 additional common shares, par value $0.001 to certain investors
pursuant to a subscription agreement at a purchase price of $3.00 per share. As of September 30, 2025, the Company retained 85.71% of
the equity in NeuroNos, with minority interest holding 14.29% ownership of NeuroNos.

SCHEDULE
OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT 

The
following table summarizes financial performance by business segment for the three months ended September 30, 2025:

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
    NeuroNos  
    Total 
  
    Capital expenditures 
    $246  
    $-  
    $-  
    $246 

    Revenues 
    $1,818  
    $-  
    $-  
    $1,818 
  
    Cost of revenues 
     (2,116) 
     -  
     -  
     (2,116)
  
    Research and development 
     (1,696) 
     (379) 
     (375) 
     (2,450)
  
    Selling, general, and administrative 
     (3,734) 
     (760) 
     (419) 
     (4,913)
  
    Loss from operations 
     (5,728) 
     (1,139) 
     (794) 
     (7,661)
  
    Interest and finance expense 
     (639) 
     -  
     -  
     (639)
  
    Other non-operating income/(expense) 
     24  
     13  
     5  
     42 
  
    Net loss before income taxes 
    $(6,343) 
    $(1,126) 
    $(789) 
    $(8,258)
  
    Operating activities included in net loss: 

    Depreciation and amortization